Edesa Biotech, Inc. is a biopharmaceutical company. The company is headquartered in Markham, Ontario and currently employs 10 full-time employees. The firm is focused on the development of therapeutics for dermatological and gastrointestinal indications. The Company’s lead product candidate, EB01, is a novel non-steroidal anti-inflammatory molecule (sPLA2 inhibitor) for the treatment of chronic allergic contact dermatitis. The firm has its operations in the United States and in Canada.